Related Experiment Video
Updated: Apr 20, 2026
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Serum cyfra21-1 as a biomarker in patients with nonsmall cell lung cancer
Hongjie Zhao, Xuejun Shi, Jinbo Liu
1Department of Thoracic Surgery, Bao Di Hospital, Bao Di Clinical College of Tianjin Medical University, Tianjin 301800, China.
Objective:
The purpose of this retrospective study was to evaluate the clinical value of serum cytokeratin-19-fragment (cyfra21-1) as a biomarker in nonsmall cell lung cancer (NSCLC).
Methods:
Sixty-six patients with NSCLC and 48 cases with benign lung disease were retrospectively analyzed in the department of thoracic surgery in our hospital. The serum level of cyfra21-1 was detected in the above patients. The diagnosis sensitivity, specificity and the receiver operating characteristic curve were calculated by using the stata11.0 statistical software to evaluate the clinical diagnosis value of serum Cyfra21-1 as NSCLC serologic biomarker.
Results:
The mean of serum cyfra21-1 were 8.95 eat. 01 μ/L and 4.28 eat. 89 μ/L in NSCLC patient and control groups respectively, which indicated that the NSCLC group were much higher (P < 0.05). The diagnosis sensitivity and specificity were 77.08% and 63.64% at the threshold of 6.32 μ/L respectively. Moreover, the area under the curve was 0.78 (95% confidence interval: 0.70-0.87).
Conclusion:
Serum cyfra21-1 can be a potential serologic biomarker in evaluation of NSCLC.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
08:14MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017